The Company has issued shares in two classes: ordinary shares and preference shares. All issued shares are fully paid up and freely transferable.
After the issues registered on March 6, 2025, the number of shares amounts to 4,290,764, of which 2,699,620 are ordinary shares and 1,591,144 are preference shares, and the share capital amounts to SEK 17,163,056 with a quota value of SEK 4.0.
At a general meeting, each ordinary share is entitled to one (1) vote. Each preference share is entitled to one-tenth (1/10) of a vote. Shareholders normally have a preferential right to subscribe to new shares, warrants and convertible debt instruments in accordance with the Swedish Companies Act, unless the general meeting or the Board, with the authority of the general meeting, decides on an exception to the preferential rights of the shareholders. All ordinary shares carry equal entitlement to a share of the Company’s assets and profits. In the event of the liquidation of the Company, holders of ordinary shares are entitled to a share of the surplus in relation to the number of shares held by the shareholder.
The preference share is subject to a redemption clause and entails in the event of (i) the Company’s divestment of more than half of the shares in the wholly owned subsidiary Chordate Medical AB, CIN 556682-5062 (“the Operating Company”), (ii) the Company’s or the Operating Company’s divestment of the entire operations and assets and liabilities in the Operating Company, (iii) a bona fide offer for the Company (including the Operating Company) of which the Company becomes aware, or (iv) liquidation of the Operating Company or the Operating Company’s bankruptcy (each such event a “Preference Dividend Event”) entitlement to a distribution of a maximum of SEK 12 (“Preference Amount”) per preference share with precedence over the ordinary shares. Otherwise, the preference shares are not entitled to any dividend or share of distribution.
Following a Preference Dividend Event, the Board of Directors can also decide on the redemption of preference shares instead of conducting a dividend. Furthermore, it will not be possible to pay dividends on ordinary shares until the Preference Amount has been paid in full to the holders of preference shares regardless of whether a Preference Dividend Event occurred or not.
Chordate’s shares have been issued in accordance with Swedish law and are denominated in SEK. The company’s shares are registered with Euroclear in electronic form and Euroclear also keeps the company’s share book.
The company’s shares have been traded on Nasdaq First North Growth Market since February 15, 2022.
ISIN: SE0022726139
Stock symbol: CMH
Nasdaq First North Growth Market is an alternative marketplace run by the various stock exchanges included in NASDAQ. It has the same legal status as a regulated exchange. Companies on Nasdaq First North Growth Market are regulated by Nasdaq First North Growth Market’s rules and not by the legal requirements that are demanded for trading on a regulated exchange. An investment in a company that is traded on Nasdaq First North Growth Market carries more risk than an investment in a company listed on a regulated exchange. All companies, whose stock is listed for trading on Nasdaq First North Growth Market, have a Certified Advisor who assures that all regulations are observed. NASDAQ Stockholm approves applications to be included in trading on Nasdaq First North Growth Market.
Vator Securities AB
+46 8 5800 6599
ca@vatorsec.se
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.
Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31
Delivery: Hanstavägen 31, 164 53 Kista
